BioPharma Resources

Drug Trial Radar · NCT04370925

Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

A Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy After Colectomy in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

Last checked: Nov 19, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 688 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

688

Planned (sponsor's estimate)

Start

Jun 4, 2020

Primary completion

Apr 30, 2024

Study completion Apr 30, 2026

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Nanfang Hospital, Southern Medical University; Sun Yat-sen University; Sixth Affiliated Hospital, Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial People's Hospital; Meizhou People's Hospital; First People's Hospital of Foshan; Shantou Central Hospital; Jiangmen Central Hospital; Shenzhen Second People's Hospital; Zhongshan People's Hospital, Guangdong, China; ZhuHai Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing Hospital; Peking University Cancer Hospital & Institute; Peking University People's Hospital; Fudan University; The Second Affiliated Hospital of Chongqing Medical University; Chongqing University Cancer Hospital; First Affiliated Hospital of Chongqing Medical University; Second Affiliated Hospital, Zhejiang University, School of Medicine; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Renmin Hospital of Wuhan University; Wuhan University; Sichuan Provincial People's Hospital; West China Hospital; The People's Hospital of Leshan; People's Hospital of Deyang City; Hebei Medical University Fourth Hospital; The First Affiliated Hospital of Nanchang University; The Affiliated Hospital Of Southwest Medical University; The Affiliated Hospital of Xuzhou Medical University; People's Hospital of Guangxi Zhuang Autonomous Region; The Third People's Hospital of Chengdu; The Affiliated Tumor Hospital of Guangxi Medical University
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy of adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.

Conditions

  • Colorectal Cancer

Interventions

  • Radical colectomyProcedure

    Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)

  • HIPECProcedure

    HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.

  • Systemic chemotherapyDrug

    Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients. CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles. mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles. For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peritoneal recurrence free survivalTime frame: 3-year

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University Cancer Hospital & Institute

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The First People's Hospital of FoShan (Affiliated FoShan Hospital of Sun Yat-sen University)

    Foshan, Guangdong, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Guangdong Provincal people's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Six Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • JiangMen Central Hospital Affiliated JiangMen Hospital Of SUN YAT-SEN University

    Jiangmen, Guangdong, China · Not yet recruiting

  • MeiZhou People's Hospital

    Meizhou, Guangdong, China · Recruiting

  • Affiliated Shantou Hospital of Sun Yat-sen University

    Shantou, Guangdong, China · Not yet recruiting

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • Zhongshan City People's Hospital

    Zhongshan, Guangdong, China · Not yet recruiting

  • Zhuhai People's Hospital, Zhuhai hospital affiliated with Jinan University

    Zhuhai, Guangdong, China · Not yet recruiting

  • People's hospital of guangxi zhuang autonomous region

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Hebei Medical University Fourth Hospital

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Union Hospital,Tongji Medical College, Huazhong Uninersity of Science and Technolgy

    Wuhan, Hubei, China · Recruiting

  • Wuhan University Renmin Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Not yet recruiting

  • the First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • The Third Peoples' Hospital of Chengdu

    Chengdu, Sichuan, China · Not yet recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • People'S Hospital of Deyang City

    Deyang, Sichuan, China · Not yet recruiting

  • Leshan people's Hospital

    Leshan, Sichuan, China · Not yet recruiting

  • The Affiliated hospital of southwest medical university

    Luzhou, Sichuan, China · Not yet recruiting

  • The Second Affiliated Hospital,Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.